Ultragenyx Pharmaceutical Inc. (RARE) Misses Q2 EPS by 3c

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) reported Q2 EPS of ($0.45), $0.03 worse than the analyst estimate of ($0.42).

For earnings history and earnings-related data on Ultragenyx Pharmaceutical Inc. (RARE) click here.

You May Also Be Interested In

• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• Carvana (CVNA) PT Lowered to $85 at RBC Capital
• H.C. Wainwright Reiterates Buy Rating on Anixa Biosciences (ANIX)